Krill oil attenuates left ventricular dilatation after myocardial infarction in rats

Lipids in Health and Disease

Erik Øie¹  Leif E Vinge²  Lars Gullestad²  Pål Aukrust³  Hogne Vik⁵  Kjetil Berge⁵  Jan O Beitnes²  Rolf K Berge⁴  Linn E Fosshaug¹ 

[1] Centre for Heart Failure Research, University of Oslo, Oslo, Norway;Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway;Research Institute for Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway;Department of Heart Disease, Haukeland University Hospital, Bergen, Norway;Aker BioMarine ASA, Oslo, Norway

关键词: lipids;    n-3 polyunsaturated fatty acids;    Heart failure;   

Others  :  1212342
DOI  :  10.1186/1476-511X-10-245

 received in 2011-11-29, accepted in 2011-12-29,  发布年份 2011

【 摘 要 】

Background

In the western world, heart failure (HF) is one of the most important causes of cardiovascular mortality. Supplement with n-3 polyunsaturated fatty acids (PUFA) has been shown to improve cardiac function in HF and to decrease mortality after myocardial infarction (MI). The molecular structure and composition of n-3 PUFA varies between different marine sources and this may be of importance for their biological effects. Krill oil, unlike fish oil supplements, contains the major part of the n-3 PUFA in the form of phospholipids. This study investigated effects of krill oil on cardiac remodeling after experimental MI. Rats were randomised to pre-treatment with krill oil or control feed 14 days before induction of MI. Seven days post-MI, the rats were examined with echocardiography and rats in the control group were further randomised to continued control feed or krill oil feed for 7 weeks before re-examination with echocardiography and euthanization.

Results

The echocardiographic evaluation showed significant attenuation of LV dilatation in the group pretreated with krill oil compared to controls. Attenuated heart weight, lung weight, and levels of mRNA encoding classical markers of LV stress, matrix remodeling and inflammation reflected these findings. The total composition of fatty acids were examined in the left ventricular (LV) tissue and all rats treated with krill oil showed a significantly higher proportion of n-3 PUFA in the LV tissue, although no difference was seen between the two krill oil groups.

Conclusions

Supplement with krill oil leads to a proportional increase of n-3 PUFA in myocardial tissue and supplement given before induction of MI attenuates LV remodeling.

【 授权许可】

   
2011 Fosshaug et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina R, Dean V, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008, 29:2388-2442.
• [2]Mann DL: Mechanisms and models in heart failure: A combinatorial approach. Circulation 1999, 100:999-1008.
• [3]Neubauer S: The failing heart-an engine out of fuel. N Engl J Med 2007, 356:1140-1151.
• [4]Stanley WC, Recchia FA, Lopaschuk GD: Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005, 85:1093-1129.
• [5]Investigators G-P: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999, 354:447-455.
• [6]Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G: Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223-1230.
• [7]Saravanan P, Davidson NC, Schmidt EB, Calder PC: Cardiovascular effects of marine omega-3 fatty acids. Lancet 2010, 376:540-550.
• [8]Duda MK, O'Shea KM, Stanley WC: omega-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential. Cardiovasc Res 2009, 84:33-41.
• [9]Weihrauch JL, Posati LP, Anderson BA, Exler J: Lipid conversion factors for calculating fatty acid contents of foods. J Am Oil Chem Soc 1977, 54:36-40.
• [10]Lu FS, Nielsen NS, Timm-Heinrich M, Jacobsen C: Oxidative stability of marine phospholipids in the liposomal form and their applications. Lipids 2011, 46:3-23.
• [11]Cohn JS, Wat E, Kamili A, Tandy S: Dietary phospholipids, hepatic lipid metabolism and cardiovascular disease. Curr Opin Lipidol 2008, 19:257-262.
• [12]O'Shea KM, Chess DJ, Khairallah RJ, Hecker PA, Lei B, Walsh K, Des Rosiers C, Stanley WC: omega-3 Polyunsaturated fatty acids prevent pressure overload-induced ventricular dilation and decrease in mitochondrial enzymes despite no change in adiponectin. Lipids Health Dis 9:95.
• [13]Duda MK, O'Shea KM, Lei B, Barrows BR, Azimzadeh AM, McElfresh TE, Hoit BD, Kop WJ, Stanley WC: Dietary supplementation with omega-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload. Cardiovasc Res 2007, 76:303-310.
• [14]Duda MK, O'Shea KM, Tintinu A, Xu W, Khairallah RJ, Barrows BR, Chess DJ, Azimzadeh AM, Harris WS, Sharov VG, Sabbah HN, Stanley WC: Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc Res 2009, 81:319-327.
• [15]Shah KB, Duda MK, O'Shea KM, Sparagna GC, Chess DJ, Khairallah RJ, Robillard-Frayne I, Xu W, Murphy RC, Des Rosiers C, Stanley WC: The cardioprotective effects of fish oil during pressure overload are blocked by high fat intake: role of cardiac phospholipid remodeling. Hypertension 2009, 54:605-611.
• [16]Ghio S, Scelsi L, Latini R, Masson S, Eleuteri E, Palvarini M, Vriz O, Pasotti M, Gorini M, Marchioli R, Maggioni A, Tavazzi L: Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. Eur J Heart Fail 2010, 12:1345-1353.
• [17]Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, Gheorghiade M, Dei Cas L: Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol 2011, 57:870-879.
• [18]Spinale FG: Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007, 87:1285-1342.
• [19]McGrath MF, de Bold ML, de Bold AJ: The endocrine function of the heart. Trends Endocrinol Metab 2005, 16:469-477.
• [20]Maytin M, Colucci WS: Molecular and cellular mechanisms of myocardial remodeling. J Nucl Cardiol 2002, 9:319-327.
• [21]Zeghichi-Hamri S, de Lorgeril M, Salen P, Chibane M, de Leiris J, Boucher F, Laporte F: Protective effect of dietary n-3 polyunsaturated fatty acids on myocardial resistance to ischemia-reperfusion injury in rats. Nutr Res 2010, 30:849-857.
• [22]Abdukeyum GG, Owen AJ, McLennan PL: Dietary (n-3) long-chain polyunsaturated fatty acids inhibit ischemia and reperfusion arrhythmias and infarction in rat heart not enhanced by ischemic preconditioning. J Nutr 2008, 138:1902-1909.
• [23]Hu FB, Manson JE, Willett WC: Types of dietary fat and risk of coronary heart disease: a critical review. J Am Coll Nutr 2001, 20:5-19.
• [24]Kong JY, Rabkin SW: Palmitate-induced apoptosis in cardiomyocytes is mediated through alterations in mitochondria: prevention by cyclosporin A. Biochim Biophys Acta 2000, 1485:45-55.
• [25]Harris WS, Sands SA, Windsor SL, Ali HA, Stevens TL, Magalski A, Porter CB, Borkon AM: Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. Circulation 2004, 110:1645-1649.
• [26]McMillin JB, Bick RJ, Benedict CR: Influence of dietary fish oil on mitochondrial function and response to ischemia. Am J Physiol 1992, 263:H1479-1485.
• [27]Batetta B, Griinari M, Carta G, Murru E, Ligresti A, Cordeddu L, Giordano E, Sanna F, Bisogno T, Uda S, Collu M, Bruheim I, Di Marzo V, Banni S: Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr 2009, 139:1495-1501.
• [28]Maki KC, Reeves MS, Farmer M, Griinari M, Berge K, Vik H, Hubacher R, Rains TM: Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women. Nutr Res 2009, 29:609-615.
• [29]Ulven SM, Kirkhus B, Lamglait A, Basu S, Elind E, Haider T, Berge K, Vik H, Pedersen JI: Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA, in healthy volunteers. Lipids 2011, 46:37-46.
• [30]Øie E, Vinge LE, Tønnessen T, Grøgaard HK, Kjekshus H, Christensen G, Smiseth OA, Attramadal H: Transient, isopeptide-specific induction of myocardial endothelin-1 mRNA in congestive heart failure in rats. Am J Physiol 1997, 273:H1727-1736.
• [31]Wergedahl H, Liaset B, Gudbrandsen OA, Lied E, Espe M, Muna Z, Mork S, Berge RK: Fish protein hydrolysate reduces plasma total cholesterol, increases the proportion of HDL cholesterol, and lowers acyl-CoA:cholesterol acyltransferase activity in liver of Zucker rats. J Nutr 2004, 134:1320-1327.